**Introduction:** Gout is a common and often debilitating inflammatory arthritis caused by monosodium urate crystal deposition in joints. It is caused by impaired excretion or increased production of urate which lead to hyperuricaemia. The presence of tophi suggest widespread crystal deposition. The tophi can cause pain, become infected or cause decreased functioning depending on their location. It is therefore important to prevent treat gout attacks and hyperuricaemia to reduce tophi formation. Treatment should target a serum urate level below 300mol/L. Xanthine oxidase inhibitors are the first line agents used to lower serum uric acid. Allopurinol, a xanthine oxidase inhibitor, is currently the first line choice according to the most recent BSR guideline. This case highlights the challenges of managing severe tophaceous gout in a patient with renal and cardiac failure.

**Case description:** The case is of a 60-year-old gentleman who was first diagnosed with gout aged 34 by his GP. In addition to gout he had multiple co-morbidities including ischaemic heart disease, mild LV Dysfunction, type 2 diabetes, hyperthyroidism, hypertension, atrial fibrillation and osteoarthritis. Initially, he had a recurring acute inflammatory mono-arthritis. Over the next few years he developed a polyarticular arthritis. This responded to Indomethacin during acute episodes. He was first seen by the Rheumatology team in 2005 after developing tophi in his fingers. Knee aspiration confirmed uric acid crystals and a serum urate was recorded to be 709mol/L. The patient was commenced on Allopurinol and titrated up to 400mg, but his compliance to this was poor initially as this triggered gout attacks. Allopurinol was recommenced with Colchicine cover and urate levels gradually improved However they remained significantly elevated, not dropping below 400mol/L. In 2011, the gentleman was discovered to have chronic renal impairment with a creatinine of 145. This complicated the management of his gout as his Allopurinol dose had to be adjusted according to renal function. Despite receiving several years of allopurinol therapy, the patient's urate levels failed to normalise and the tophaceous gout began causing problems. Acute flares continued despite the use of low dose Prednisolone at 5mg and long term colchicine. As the required target reduction of serum urate was not achieved using Allopurinol, the patient was switched to Febuxostat at a dose of 80mg in 2015. This induced a significant gradual reduction in serum urate levels and, most recently, he was found to have a serum urate of 325mol/L. This, however, is the only result to date below the 400mol/L and the current treatment aim is to improve on this and achieve a serum urate below the target of 300mol/L. The effects of the tophaceous deposits on the patient were considerable. He suffered from mobility problems resulting from the deposits on the feet. The use of hands was impaired by the numerous large tophi on his fingers. Additionally, he developed tophi on his groin and genital which were very distressing. He suffered further impairment to his renal function resulting from bilateral nephrolithiasis and required a left sided uretocopy and stone removal in 2013.

**Discussion:** Our patient's serum urate was pivotal to improving this. Combined cardiac and renal impairment complicated his management. His renal impairment prevented optimal dosing of Allopurinol. The latest BSR guidance suggests that the second line agent should be Febuxostat, another xanthine oxidase inhibitor. Febuxostat is contraindicated in patients with ischaemic heart disease or congestive cardiac failure. This recommendation is based on the initial Phase 3 RCT trials comparing Febuxostat to Allopurinol and placebo which found increased cardiovascular risk. However, since these trials, small scale studies suggest that Febuxostat may not have a significant impact on cardiovascular disease. As a result, this question is currently being evaluated in larger scale studies. We used Febuxostat despite the patient having ischaemic heart disease, as Allopurinol was ineffective at reducing his uric acid levels and his gout was severe. Gouty tophi can be difficult to treat. 80mg of Febuxostat has improved our patient's serum urate levels. Despite this, his gouty tophi persist and continue to be very debilitating. The optimal treatment of tophi is a subject of debate and trials suggest that this is best achieved by maintaining a serum urate level below 360mol/L (3). Alternative treatment options include Uricosuric agents such as Prebenecid. However, these agents are contraindicated in patients with renal stones and are also less effective in patients with reduced glomerular filtration rate.

**Key learning points:** 1 Allopurinol doses need to be reduced in renal impairment but these doses are often ineffective. Uricosuric agents are also less effective in renal impairment. 2 Febuxostat can be used in renal impairment but is not recommended in cardiac disease. 3 The treatment of tophi requires an extended period of reduced serum urate. This necessitates good control of urate levels with uric acid lowering therapy. 4 Tophi present commonly in the extremities but can present in unexpected areas such as was the case in this patient.
